Daxor Corporation Appoints Michael Feldschuh as Executive Vice President

NEW YORK, NY--(Marketwired - Dec 18, 2014) - Daxor Corp (NYSE MKT: DXR) announced today that it has appointed Michael Feldschuh as Executive Vice President, to head business development and strategic initiatives for Daxor Corporation as part of the firm's effort to build its medical device business.

"We have exciting strategic goals for our medical device business, and Michael's appointment represents a significant step forward in its ongoing development," said Dr. Joseph Feldschuh, President and CEO of Daxor. "Michael joins us after having served for the past year and half on our Board of Directors and brings a wealth of management experience from his years of work on Wall Street in addition to his excellent analytical skills and strong investment experience. We are pleased that he has made the jump to our executive team to head up the next phase of our initiatives."

Michael joins Daxor after having headed his own hedge fund, Aristarc Capital, from 2009 to 2013. Prior to founding his own fund, Michael was a Managing Director at Morgan Stanley from 2005 to 2009 and also served as a Managing Director and Portfolio Manager at Millennium Partners in New York from 1997-2005. Michael was a proprietary trader for Morgan Stanley & Co. from 1994-1997. Michael began his career E. Shaw & Co. in New York, where he worked with Jeffrey Bezos prior to Bezos's founding of Amazon. He was granted a bachelors degree following the completion of his Pre-Med studies at Columbia College, Columbia University in 1991.

"Bringing Michael and the team that he will build to focus on our business strategies is a key part of our plan to strengthen and grow our focus on the BVA-100 business," said Bernhard Saxe, a member of the Daxor Board of Directors. "Another part is expanding our efforts to embrace the latest quantitative tools and social media to expand the reach of our message to both institutions and patients, and I believe Michael and his team will make key contributions to each."

"Daxor has unique technology that will be transformative in how a number of widespread conditions are treated. I am thrilled to head the next phase of the company's development which is the widespread commercial adoption of our products on a global scale," said Michael. 

The Daxor Corporation has performed over 30,000 patient tests with its revolutionary FDA-approved BVA-100 system, the most accurate and effective tool available to treat a broad range of indications for which blood-volume derangements are a key piece of patient care. Uses for the machine include, but are not limited to, septic shock, heart failure, kidney failure, dialysis, syncope, oncology, and blood loss from surgery and trauma. The device is installed in over 70 locations in the United States including facilities such as the National Institutes of Health, the Cleveland Clinic, and the NYU Hospital Center.

Daxor Corporation is the manufacturer of the BVA-100 Blood Volume Analyzer, the only FDA approved semi-automated blood volume analyzer.